Core Viewpoint - TELA Bio, Inc. is set to report its third quarter 2024 financial results on November 7, 2024, and will host a conference call and webcast to discuss these results and provide a corporate update [1]. Group 1: Financial Reporting - The third quarter 2024 financial results will be announced on November 7, 2024 [1]. - A conference call and webcast will take place at 4:30 p.m. ET on the same day to discuss the financial results [1]. Group 2: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions [3]. - The company aims to optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy [3]. - TELA Bio is committed to providing advanced, economically effective solutions that leverage the patient's natural healing response while minimizing long-term exposure to synthetic materials [3].

TELA Bio, Inc. (TELA) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.46 per share a year ago. These figures are adjusted for nonrecurring items. This quarterly report represents an earnings surprise of -13.33%. A quarter ago, it was expected that this company would post a loss of $0.48 per share when it actually produced a loss of $0.23, delivering a surprise of 52.08%. Over the last four quarters, the company has surpass ...

MALVERN, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Reported revenue of $16.1 million in the second quarter, representing growth of 11% over the prior year period of 2023; Appointed Greg Firestone as Chief Commercial Officer on May 20, 2024 to drive our next phase of revenue g ...

Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions that optimize clinical outcomes by preserving and restoring the patient's own anatomy [3] Recent Developments - The Compensation Committee of TELA Bio's Board of Directors approved inducement grants of restricted stock units covering 16,000 shares to nine newly-hired employees, with a grant date of August 6, 2024 [1] - The restricted stock units will vest in equal annual installments over four years, contingent on each individual's continued service with TELA Bio [2]

Core Viewpoint - TELA Bio, Inc. is set to report its second quarter 2024 financial results on August 12, 2024, and will host a conference call and webcast to discuss these results and provide a corporate update [1]. Group 1: Financial Reporting - The second quarter 2024 financial results will be reported on August 12, 2024 [1]. - A conference call and webcast will take place at 4:30 p.m. ET on the same day to discuss the financial results [1]. Group 2: Company Overview - TELA Bio, Inc. is a commercial-stage medical technology company focused on innovative soft-tissue reconstruction solutions [3]. - The company aims to optimize clinical outcomes by preserving and restoring the patient's own anatomy while minimizing long-term exposure to synthetic materials [3].

MALVERN, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (Nasdaq: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced that it has appointed Jeffrey Blizard, the Global Head of Surgical Sales for Abiomed, a medical device technology company that operates as a stand-alone business within Johnson & Johnson's MedTech Segment, to its Board of Directors, effective June 4, 2024. "We are excited to have Jeff jo ...

"I would also like to extend my deepest appreciation to Peter Murphy for his many contributions to TELA Bio and guiding us through our initial periods of continuous growth," said Antony Koblish. "We are confident that Greg's leadership will build upon and sustain this success." To learn more about TELA Bio, visit telabio.com About TELA Bio, Inc. MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial- stage medical technology company focused on providing innovative soft-ti ...

MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial- stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today announced the appointment of Greg Firestone as the Company's new Chief Commercial Officer. In this role, Mr. Firestone will oversee the Company's commercial operations, including key product launches, sales team training, market development, as well as strategic initiatives to optimize market access and reimbu ...

Financial Data and Key Metrics Changes - Revenue for Q1 2024 grew 39% year-over-year to $16.6 million, marking the 13th consecutive quarter of growth of 35% or greater [7][94] - Gross margin increased to 68% from 66% in the prior year, primarily due to improved inventory management [82] - Operating loss decreased to $4.8 million from $11.3 million in the prior year, with net loss reduced to $5.7 million from $12 million [70] Business Line Data and Key Metrics Changes - OviTex revenue grew 31%, while OviTex PRS saw a 54% increase in the same period, driven by higher unit sales and expansion of the commercial organization [7][96] - PRS now accounts for over a third of total sales, with the long-term resorbable configuration making up 55% of the PRS portfolio [96] Market Data and Key Metrics Changes - The company engaged with surgeons at 25 industry meetings through March 2024, enhancing its presence in the market [20] - Over 50,000 units of OviTex have been used in hernia and complex abdominal wall procedures, indicating strong market penetration [96] Company Strategy and Development Direction - The company aims to capitalize on the momentum generated in Q4 2023, focusing on product launches and enhancements to the commercial team [4] - TELA Bio is positioned to compete effectively with larger competitors, leveraging a complete product portfolio and strong clinical data [67][100] Management's Comments on Operating Environment and Future Outlook - Management expects operating loss and net loss to decrease in 2024 compared to 2023, with steady operating expenses and sequential revenue growth [8] - The company is optimistic about the potential of LIQUIFIX and IHR products to open new market opportunities [9][12] Other Important Information - The company ended Q1 2024 with $37.1 million in cash and cash equivalents, indicating a strong financial position [70] - A strategic hire was made with Dr. Howard Langstein joining as Vice President of Medical Affairs to drive awareness of TELA's products [62] Q&A Session Summary Question: How do you feel about cash burn this quarter and how you expect that to trend throughout the year? - Management expressed confidence in cash burn management, anticipating steady operational expenses and revenue growth to improve profitability metrics [48] Question: Can you provide an update on your GPO contracts and how you're ramping there? - The company is actively pursuing access via IDNs and smaller GPOs, with positive dynamics expected for future contracts [107][119] Question: What are the sequential expectations for Q2? - Management noted that Q2 is typically a strong quarter and expressed optimism about growth driven by a fully staffed sales organization and new product introductions [44] Question: How is productivity trending, including initiatives for balanced selling? - New reps are averaging just under six months to reach breakeven, with a balanced selling approach showing early signs of success [47][29] Question: What is the contribution expected from IHR for this year? - IHR is anticipated to have a quick uptake among surgeons already using TELA's products, contributing positively to revenue [105] Question: Can you elaborate on the impact of the synthetic mesh lawsuit? - Management is monitoring the situation closely and has a communication plan in place to address potential outcomes [71][86]

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 For the transition period from ____ to ____ Commission File Number: 001-39130 TELA Bio, Inc. (Exact name of registrant as specified in its charter) Delaware (State or othe ...